GLP-1 receptor agonists and the risk of postoperative nausea and vomiting after laparoscopic sleeve gastrectomy: a single-center, retrospective cohort study

📖 Top 20% JournalOct 31, 2024Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery

GLP-1 receptor drugs and the risk of nausea and vomiting after laparoscopic sleeve gastrectomy

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Preoperative exposure to GLP-1 receptor agonists is associated with a 6.782 times higher risk of postoperative nausea and vomiting after laparoscopic sleeve gastrectomy.

62.2% of patients experienced postoperative nausea and vomiting (PONV) after laparoscopic sleeve gastrectomy (LSG).
Among patients exposed to GLP-1 receptor agonists, 84.7% experienced PONV compared to 58.2% of those not exposed.
In a matched cohort of 158 patients, PONV occurred in 83.5% of those exposed to GLP-1 receptor agonists and 60.8% of those not exposed.
Higher doses of GLP-1 receptor agonists are positively associated with an increased risk of PONV after LSG.

AI simplified

BACKGROUND: Whether preoperative exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with postoperative nausea and vomiting (PONV) after laparoscopic sleeve gastrectomy (LSG) remains unclear.

OBJECTIVES: To investigate the association between preoperative GLP-1RAs exposure and PONV after LSG.

SETTING: University Hospital, China.

METHODS: We reviewed a retrospective cohort of patients underwent LSG between January 1, 2017, and December 30, 2021 at Nanjing Drum Tower Hospital, dividing the patients into 2 groups on the basis of whether they were exposed to GLP-1RAs preoperatively. A 1:1 propensity score matching was performed to balance the characteristics between the groups. Associations between GLP-1RAs exposure and PONV were determined by logistic regressions.

RESULTS: A total of 564 eligible patients underwent LSG, 351 (62.2%, 95% CI 58.2-66.1) of whom had PONV. In total cohort, PONV occurred in 72(84.7%) patients exposed to GLP-1RAs preoperatively and 279 (58.2%) patients not exposed to GLP-1RAs (adjusted odds ratio 6.782, 95% confidence interval 3.307-13.907, P < .001). In the 158 matched patients, PONV occurred in 66 (83.5%) patients exposed to GLP-1RAs preoperatively and 48 (60.8%) matched patients not exposed to GLP-1RAs (adjusted odds ratio 3.830, 95% confidence interval 1.461-10.036, P = .006). Subgroup analysis by dosage forms and doses revealed a positive association between greater doses and an increased risk of PONV after LSG for both once-daily and once-weekly formulations.

CONCLUSIONS: Preoperative exposure to GLP-1RAs is associated with an increased risk of PONV in patients undergoing LSG, particularly at higher doses of exposure.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗